公开(公告)号：US11666874B2

公开(公告)日：2023-06-06

申请号：US16052705

申请日：2018-08-02

申请人： Massachusetts Institute of Technology

发明人： David Lai ,  Filippos Touriomousis ,  Andreas Mershin ,  Neil Gershenfeld

IPC分类号： B01F23/41 ,  B01F33/3011 ,  C09D11/102 ,  A61K9/107 ,  B33Y80/00 ,  B01L3/00 ,  B01F33/81 ,  B01F35/00 ,  B01F35/22 ,  B01F101/22

CPC分类号： B01F33/3011 ,  A61K9/107 ,  B01F23/41 ,  B01F33/813 ,  B01F35/2202 ,  B01F35/561 ,  B01L3/502784 ,  B33Y80/00 ,  C09D11/102 ,  B01F23/4143 ,  B01F2101/22 ,  B01L2300/0887

摘要： The invention comprises a novel modular, generalizable meso-micro-nano-fluidic platform apparatus, design and methodology which in exemplary embodiments may be applied in conjunction with a novel external triggering and automation/feedback loop control mechanism deployed via computer to explore the phase space of single or double emulsification for applications including the encapsulation of hydrophilic active pharmacological ingredients (APIs). End use applications include the mass production of particulate encapsulation of hydrophobic or hydrophilic APIs with automatic or user-supervised feedback methodology to control and discover mass production or per-drug customized settings of interest for the manufacture of novel or extant therapeutics. This invention allows for a process to produce monodispersed particles of varying sizes and may be used to rapidly screen for optimal size for maximal bioavailability of API particles either on lab bench for in vitro dissolution or in vivo studies, and patient-specific handhelds for maximal drug inhalation.

公开(公告)号：US20190184351A1

公开(公告)日：2019-06-20

申请号：US16052705

申请日：2018-08-02

申请人： Massachusetts Institute of Technology

发明人： David Lai ,  Filippos Touriomousis ,  Andreas Mershin ,  Neil Gershenfeld

IPC分类号： B01F13/00 ,  C09D11/102 ,  A61K9/107 ,  B01F3/08 ,  B33Y80/00

CPC分类号： B01F13/0062 ,  A61K9/107 ,  B01F3/0807 ,  B01F2003/0834 ,  B01F2215/0032 ,  B33Y80/00 ,  C09D11/102

摘要： The invention comprises a novel modular, generalizable meso-micro-nano-fluidic platform apparatus, design and methodology which in exemplary embodiments may be applied in conjunction with a novel external triggering and automation/feedback loop control mechanism deployed via computer to explore the phase space of single or double emulsification for applications including the encapsulation of hydrophilic active pharmacological ingredients (APIs). End use applications include the mass production of particulate encapsulation of hydrophobic or hydrophilic APIs with automatic or user-supervised feedback methodology to control and discover mass production or per-drug customized settings of interest for the manufacture of novel or extant therapeutics. This invention allows for a process to produce monodispersed particles of varying sizes and may be used to rapidly screen for optimal size for maximal bioavailability of API particles either on lab bench for in vitro dissolution or in vivo studies, and patient-specific handhelds for maximal drug inhalation.